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Background: Preoperative systemic chemotherapy is increasingly used in patients who undergo hepatic
resection for colorectal liver metastases (CLM). Although chemotherapy-related hepatic injury has been
reported, the incidence and the effect of such injury on patient outcome remain ill defined.
Methods: A systematic review of relevant studies published before May 2006 was performed. Studies that
reported on liver injury associated with preoperative chemotherapy for CLM were identified and data
on chemotherapy-specific liver injury and patient outcome following hepatic resection were synthesized
and tabulated.
Results: Hepatic steatosis, a mild manifestation of non-alcoholic fatty liver disease (NAFLD), may
occur after treatment with 5-fluorouracil and is associated with increased postoperative morbidity. Non-
alcoholic steatohepatitis, a serious complication of NAFLD that includes inflammation and hepatocyte
damage, can occur after treatment with irinotecan, especially in obese patients. Irinotecan-associated
steatohepatitis can affect hepatic reserve and increasemorbidity andmortality after hepatectomy.Hepatic
sinusoidal obstruction syndrome can occur in patients treated with oxaliplatin, but does not appear to be
associated with an increased risk of perioperative death.
Conclusion: Preoperative chemotherapy for CLM induces regimen-specific hepatic changes that can
affect patient outcome. Both response rate and toxicity should be considered when selecting preoperative
chemotherapy in patients with CLM.
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Introduction
Surgical resection remains the standard treatment for
patients with resectable colorectal liver metastases (CLM)
and is the only single-modality therapy associated with
cure. Five-year survival rates after resection of CLM have
been reported to be as high as 58 per cent1–4, especially
when hepatic resection is combined with chemotherapy.
However, only 15–20 per cent of patients with CLM are
candidates for surgical resection at the time of diagnosis5–8.
Many patients with CLM require a multimodal
approach. Unfortunately, the response rates achieved with
the combination of 5-ﬂuorouracil (5-FU) and leucovorin
have changed little over the past 40 years and remain
at only about 20 per cent9. More recently, however,
with the introduction of new regimens that combine
ﬂuoropyrimidines with irinotecan or oxaliplatin, the
efﬁcacy of chemotherapy as a ﬁrst-line treatment for
CLM has improved dramatically. Combined with 5-FU,
irinotecan, a topoisomerase I inhibitor, and oxaliplatin,
a platinum derivative with activity against colorectal
cancer, have yielded response rates of 54–56 per cent
with a median survival of 22 months in patients with
stage IV colorectal cancer10–13. In addition to these novel
cytotoxic agents, new molecular targeted therapies have
been developed. Both bevacizumab, amonoclonal antibody
to vascular endothelial growth factor, and cetuximab, an
anti-epidermal growth factor receptor, have produced
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response rates approaching 70 per cent when combined
with cytotoxic agents14,15.
Use of these newer, more effective, regimens has
enabled downsizing of CLM, leading to resection in up to
10–13 per cent of the patients who initially presented with
irresectable disease16–19. In addition, effective treatment
for CLM has expanded the use of chemotherapy in initially
resectable patients. The rationale for using preoperative
chemotherapy in patients with initially resectable disease
includes an opportunity to demonstrate regimen-speciﬁc
efﬁcacy, as well as allowing time to identify those
patients who will develop progressive disease and who
therefore may not beneﬁt from liver resection. In addition,
preoperative chemotherapy may decrease the magnitude
of resection needed and also be associated with a lower rate
of positive margins compared with immediate resection20.
Although the use of newer chemotherapeutic agents
has a number of theoretical beneﬁts, the effect of these
agents on the underlying liver parenchyma remains ill
deﬁned. Concern about hepatic resection leaving a dam-
aged liver remnant has led investigators to examine
chemotherapy-related hepatic injuries21. Speciﬁcally, one
type of hepatic injury, sinusoidal obstruction syndrome
(SOS; previously termed veno-occlusive disease) has been
reported to be associated with liver failure and death fol-
lowing intensive systemic chemotherapy and bone marrow
transplantation22–24. More recently, other reports have
suggested an increase in the incidence of several less
well understood chemotherapy-associated liver injuries
including hepatic steatosis, steatohepatitis and sinusoidal
injury3,20,21,25. However, the effect of these histopatho-
logical changes on outcome after hepatic resection is only
beginning to be recognized and investigated.
In this article, data are synthesized from a systematic
review of the existing literature to clarify which drugs
are implicated in liver injury following preoperative
chemotherapy for CLM. In addition, the impact of drug-
speciﬁc liver injuries on outcome after hepatic resection is
assessed. These data provide the framework for discussion
of treatment strategies in stage IV colorectal cancer, and
provide a foundation for future studies that will contribute
to development of the best multimodal care plan for
patients with CLM.
Literature search strategy
Original published studies were identiﬁed by searching
the MEDLINE database (January 1966 to May 2006).
Articles were selected using keywords ‘liver injury’, ‘hepatic
resection’, ‘chemotherapy’, ‘5-ﬂuorouracil’, ‘oxaliplatin’,
and ‘irinotecan’ to identify all reports that may pertain
to liver injury following preoperative chemotherapy for
CLM. Manual cross-referencing was performed and
relevant references from selected papers were reviewed.
Chemotherapy-associated non-alcoholic fatty
liver disease
The spectrum of liver changes associated with fat
accumulation in hepatocytes is termed non-alcoholic
fatty liver disease (NAFLD)26 (Fig. 1a,b). NAFLD is
increasingly recognized as the hepatic manifestation of
insulin resistance and is part of the systemic complex
known as metabolic syndrome27,28. Based on the Third
National Health and Nutritional Examination Survey,
the prevalence of NAFLD in North America and similar
regions ranges from 3 to 23 per cent29,30, and it parallels
the ‘epidemiology’ of obesity31,32. The clinical course
of NAFLD is indolent in most patients but, in some,
a progressive form of NAFLD can lead to ﬁbrosis and
cirrhosis in the latter stage of disease33–36.
Macrovesicular steatosis, which denotes the accumu-
lation of fat in the hepatocytes, represents the mildest
manifestation of NAFLD (Fig. 1c). In contrast, steatohep-
atitis is a more serious form of NAFLD characterized by
fatty inﬁltration and inﬂammation in the liver (Fig. 1d).
The distinctive features of steatohepatitis include steato-
sis, monomorphic and neutrophilic portal and lobular
inﬂammation, and perisinusoidal ﬁbrosis in lobular zone 3.
Other common morphological features are hepatocellular
ballooning, poorly formed Mallory’s hyaline, and glyco-
genated nuclei (Fig. 1d). The histopathological spectrum
of liver injury associated with non-alcoholic steatohepati-
tis (NASH) was ﬁrst described in 1980 by Ludwig and
colleagues37. Now recognized as a progressive form of
NAFLD, NASH can progress to cirrhosis and an increased
risk of hepatocellular carcinoma31,38,39. Whether severe
steatosis can progress to cirrhosis when inﬂammation is
absent is not known.
Although abnormal liver function tests and radiographic
ﬁndings may be suggestive of NAFLD, histological eval-
uation remains the only way to assess hepatocyte damage
accurately and to distinguishNASH from ‘simple’ steatosis,
or steatosis with inﬂammation40 (Fig. 1c,d). The grading
and staging of NAFLD is evolving; the ﬁrst system was
developed by Brunt et al.41 and more recently modiﬁed
by the Pathology Committee of the National Institute
of Health NASH Clinical Research Network42. Recently,
Kleiner and co-workers43 proposed a newNAFLD activity
score (NAS) based on regression analyses of 14 hepatic
histological features. The NAS includes three features
(steatosis grade, lobular inﬂammation and ballooning of
hepatocytes) evaluated semiquantitatively. Each of the
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a  Intraoperative view of whole fatty liver b  Cut fatty liver
c  Simple steatosis d  Steatohepatitis
Fig. 1 Spectrum of non-alcoholic fatty liver disease (NAFLD). a, b Macroscopic aspect of fatty (‘yellow’) liver. The steatotic liver is
enlarged, soft and appears yellow in colour because of fatty inﬁltration. c Simple steatosis, the mildest manifestation of NAFLD,
denotes the accumulation of large globules of fat in the hepatocytes (macrovesicular steatosis) (haematoxylin and eosin; magniﬁcation
×400). d Histopathological spectrum of non-alcoholic steatohepatitis. Various degrees of inﬂammation can be seen scattered
throughout the lobule as well as in portal tracts. Hepatocyte damage is demonstrated by scattered ballooned (arrows) and apoptotic cells
(haematoxylin and eosin; magniﬁcation ×200 for the night and left ﬁelds, ×125 for the centre)
three features of theNAS, or ‘Kleiner score’, independently
correlated with a diagnosis of NASH. The NAS was also
able to provide a clinically useful scoring of NASH (NAS 5
or more), borderline NASH (NAS 3 and 4) or ‘not NASH’
(NAS 1 and 2).
Chemotherapy-associated steatosis
Drugs implicated
A number of case reports and studies suggest that
chemotherapy for CLM can be associated with steatosis.
Zeiss and colleagues44 reported histologically documented
patchy fatty change in a patient with CLM treated with
ﬂoxuridine via a hepatic artery infusion pump. In this
patient drug administration was not equal in all parts of
the liver parenchyma, and steatosis occurred in the parts
that were overperfused. Peppercorn et al.45 found that
47 per cent of patients with CLM treated with systemic
5-FU and folinic acid had computed tomography (CT)
ﬁndings consistent with fatty change. No correlation was
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observed between liver function test results, chemotherapy
dose and the development of steatosis. Reversible steatosis
was also reported in 30 per cent of patients with metastatic
colorectal cancer treated with a combination of interferon
α and 5-FU46. One report described CT and biopsy
evidence of steatosis in 40 per cent of patients who
received adjuvant therapy with 5-FU and levamisole after
undergoing surgical resection for stage II or III colonic
cancer47. Notably, none of these initial studies reported
data on the correlation between chemotherapy-induced
hepatic steatosis and outcome following hepatic resection
in terms of morbidity or mortality.
Impact on outcome following hepatic resection
Based on data from the transplantation literature, it is
postulated empirically that each 1 per cent increase in fat
content, either microvesicular or macrovesicular, decreases
the functional mass of the donor liver by 1 per cent48.
However, whether steatosis following chemotherapy pro-
duces a similar decrease in functional hepatic mass and a
subsequent adverse outcome following hepatic resection
is unknown. A few studies have explored the association
between chemotherapy and steatosis, and have attempted
to assess the impact of steatosis on patient outcome fol-
lowing resection (Tables 1 and 2). Unfortunately, most
Table 1 Outcome after hepatic surgery correlated with chemotherapy regimen and hepatic injury
5-FU IRI OX BMI
correlates
Chemotherapy
dose/duration
Reference
Total no.
of patients
No. of
patients
Postop.
complications
No. of
patients
Postop.
complications
No. of
patients
Postop.
complications
Simple
steatosis NASH SOS
with hepatic
injury
correlates with
hepatic injury
49 135 — — — — — — Yes† — — Yes —
50 478 — — — — — — Yes† — — — —
20 108 27 10 (37) 34 10 (29) 0 0 Yes‡ — — — —
51 485 — — — — — — Yes† — — Yes —
25 153 27 — 17 — 43 — Yes§ — Yes¶ — No
52 37 10 — 10 — 4 — — Yes†# — Yes No
53 67 8 3 (38) 37* 14 (38)* 37* 14 (38)* Yes† — Yes† — Yes**
21 406 63 17 (27) 94 17 (18) 79 21 (27) Yes§ Yes†† Yes¶ Yes‡‡ No§§
Values in parentheses are percentages. Hepatic injury includes more than 30 per cent steatosis, steatohepatitis or sinusoidal dilatation. 5-FU,
5-ﬂuorouracil; IRI, irinotecan; OX, oxaliplatin; simple steatosis, mildest form of non-alcoholic liver disease; NASH, non-alcoholic steatohepatitis; SOS,
sinusoidal obstruction syndrome; BMI, body mass index. *Thirty-seven patients had IRI or OX therapy, of whom 14 developed postoperative
complications. †No stratiﬁcation of hepatic injury based on speciﬁc chemotherapy regimen. ‡Steatosis correlates with IRI regimen. §Steatosis does not
correlate with any regimen. ¶Sinusoidal dilatation correlates with OX regimen. #Steatohepatitis, graded according to a NASH score, correlates with
IRI–OX regimen. **Number of chemotherapy cycles correlates with postoperative complications. ††Steatohepatitis correlates with IRI regimen. ‡‡BMI
correlates with IRI-associated hepatic injury. §§Duration of OX or IRI therapy does not correlate with increased hepatic injury.
Table 2 Outcome after hepatic surgery correlated with chemotherapy regimen and hepatic injury
Postoperative outcome
No. of patients
Chemotherapy related
No. of patients
Hepatic injury related
Reference
who had preop.
chemotherapy Complications
Liver
failure Death
with hepatic
injury Complications
Liver
failure Death
Hepatic
injury
Chemotherapy
regimen
49 — — — — 7 − (29) − (14) − (14) Steatosis† —
50 — — — — 37 8 (22) — 0 (0) Steatosis† —
20 61 20 (33) 2 (3) 0 12 — 1 (8) 0 (0) Steatosis 5-FU, IRI
51 249 — — — 102 27 (26) 3 (3) 6 (6) Steatosis† —
25 87 — — — 44 — — — Steatosis, SOS 5-FU IRI, OX
52 24* 1 (4) 1 (4) 1 (4) — 1 (4) 1 (4) 1 (4) NASH† 5-FU, IRI, OX
53 45 17 (38) 5 (11) 0 (0) 52 — — 0 (0) Steatosis, SOS† 5-FU, IRI, OX
21 248 55 (22) — — 92 — 3 (3) 6 (7) Steatosis, NASH, SOS 5-FU, IRI, OX
Values in parentheses are percentages. Hepatic injury includes more than 30 per cent steatosis, steatohepatitis or sinusoidal dilatation. 5-FU,
5-ﬂuorouracil; IRI, irinotecan; OX, oxaliplatin; steatosis, mildest form of non-alcoholic liver disease; NASH, non-alcoholic steatohepatitis; SOS,
sinusoidal obstruction syndrome. *Results reported in general for 14 patients treated with either IRI or OX regimen, but no breakdown according to
agent. †No stratiﬁcation of hepatic injury based on speciﬁc chemotherapy regimen.
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of these studies failed to stratify data by chemotherapy
regimen and so were unable to assess whether histopatho-
logical liver changes were chemotherapy speciﬁc49–53.
Despite these limitations, a few consistent, important
ﬁndings can be derived from careful analysis of these
reports.
In 1998, Behrns and co-workers49 reported the ﬁrst
study designed to examine patient outcomes following
major hepatectomy in the setting of hepatic steatosis.
One hundred and thirty-ﬁve patients who underwent
major hepatic resection (at least four hepatic segments)
for CLM were studied, including 56 with mild (less than
30 per cent) steatosis and seven with marked (moderate to
severe) steatosis. The patients with marked steatosis had
an increased body mass index (BMI), a longer operating
time, a greater likelihood of transfusion, an increased risk
of complications and liver failure, as well as a higher post-
operative mortality rate (Table 2). It was concluded that
marked steatosis is associated with increased perioperative
morbidity and mortality after major hepatectomy. How-
ever, the small number of patients in the study with marked
steatosis limits interpretation of these ﬁndings.
Belghiti et al.50 subsequently reported on 37 patients
with marked steatosis (more than 30 per cent) who
underwent hepatic resection. They noted that, although
there was an increase in morbidity after hepatic resection
(22 per cent versus 8 per cent in the control group), there
was no difference in postoperative mortality rates based
on presence or absence of steatosis (Table 2). Furthermore,
the increase in morbidity was largely due to an increase in
infectious complications.
More recently, a study from Parikh and colleagues20
showed that preoperative treatment with irinotecan in
patients with CLM was associated with steatosis. In this
study, mild steatosis (less than 25 per cent) occurred in
15 of 34 patients who received irinotecan. In addition,
four patients who received irinotecan were noted to
have moderate (25–50 per cent) or severe (more than
50 per cent) steatosis, and one of these developed hepatic
insufﬁciency. The authors conﬁrmed that there were no
perioperative deaths in patients with simple steatosis, even
when severe (Table 2).
Kooby and co-workers51 examined 325 patients with
steatosis, 102 of whom had marked steatosis (more
than 30 per cent), who underwent hepatic resection for
treatment of a neoplasm. Like Behrns et al.49, they
observed a correlation between marked steatosis and
high BMI. An association between steatosis and previous
exposure to cytotoxic chemotherapy was also noted51.
The incidence of complications in general, and more
speciﬁcally infectious complications, correlated with the
degree of steatosis. Complication rates were signiﬁcantly
higher in the group with marked steatosis than in
the control group (overall complication rate 62 per cent
in those with marked steatosis versus 35 per cent in
controls; infective complication rate 43 versus 14 per cent
respectively; P < 0·01). Again, marked steatosis was not
signiﬁcantly associated with an increased mortality rate.
The authors concluded that steatosis should not preclude
major hepatic resection but that caution should be exercised
in patients with marked disease.
Vauthey et al.21 recently reported a systematic analysis
of the association between chemotherapy type, histopatho-
logical liver injury and postoperative outcome. In this
study, each of the 406 resected liver specimens from
patients who underwent resection for CLM underwent a
full pathological review. Liver injury was classiﬁed accord-
ing to established standards using the NAS43. Importantly,
in this study steatohepatitis was differentiated from steato-
sis as a separate pathological entity for the purposes of
outcome analyses. The authors noted that no speciﬁc
chemotherapy regimen was associated with steatosis when
steatohepatitis was excluded (Table 1). Similar to previ-
ously published data, there was no increase in mortality
after hepatic resection in patients with steatosis. However,
unlike steatosis, the pathological ﬁnding of steatohepatitis
had important implications for outcome from resection
(see below).
Chemotherapy-associated non-alcoholic
steatohepatitis
Several mechanisms have been identiﬁed that can lead
to the progression of steatosis to NASH54. Among
them, oxidative stress and the production of reactive
oxygen species due to mitochondrial dysfunction appear
to play central roles55. Recently, Laurent et al.56,57
showed that several chemotherapy drugs (for example 5-
FU, platinum derivatives and taxanes) induce oxidative
stress in both cancer cells and normal cells exposed
to chemotherapy. This chemotherapy-induced oxidative
stress in the presence of steatosis can lead to NASH. This
is consistent with the proposed ‘two-hit theory’ of NASH
pathogenesis54, in which the ﬁrst hit is steatosis and the
second hit is production of reactive oxygen species.
Drugs implicated
Two recent studies21,52 have demonstrated an increased
incidence of NASH in patients treated with preoperative
chemotherapy for CLM. Fernandez et al.52 were the ﬁrst to
report an increased incidence of NASH in patients treated
with hepatic resection after preoperative chemotherapy for
CLM. The NASH score, according to the Brunt system41,
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was noted to be signiﬁcantly higher in patients who had
received mainly irinotecan (only four patients received
oxaliplatin) than in those who had been treated with 5-FU
or who had no chemotherapy. The total dose and the
duration of administration of chemotherapy did not affect
the risk of NASH in this small cohort, but high BMI was
signiﬁcantly correlated with a high NASH score (Table 1).
The authors concluded that obese individuals were more
likely than lean individuals to develop steatohepatitis
following treatment with modern chemotherapeutic
agents. Moreover, they proposed that chemotherapy-
associatedNASH could affect hepatic reserve andmay have
implications with regard to the percentage of liver volume
that can be safely resected. In the multicentre study by
Vauthey et al.21, the association between chemotherapy
type, liver injury and the impact of liver injury on
outcome following hepatic resection for CLM was
examined. On ﬁnal pathological analysis, 23 per cent of the
patients had liver injuries, and 8 per cent of patients had
steatohepatitis as deﬁned by the NAS43. No chemotherapy
regimen was associated with steatosis when steatohepatitis
was considered as a separate entity. Only irinotecan
was associated with steatohepatitis (P < 0·001) (Table 1).
Furthermore, irinotecan was associated with an increased
risk of steatohepatitis independent of BMI, although the
risk was higher in patients with a BMI greater than
25 kg/m2. Given these ﬁndings, the authors recommended
caution when irinotecan is being considered for patients
with a BMI over 25 kg/m2, especially in individuals who
are potential candidates for major hepatic resection.
Impact on outcome after hepatic resection
Fernandez et al.52 reported on an index patient who
developed severe steatohepatitis following oxaliplatin
chemotherapy. This patient subsequently developed liver
failure and died 88 days after hepatic resection (Table 2).
Vauthey et al.21 similarly reported an increased 90-
day postoperative mortality rate in a larger cohort
of patients with steatohepatitis. Speciﬁcally, patients
with steatohepatitis had a 90-day mortality rate of
15 per cent compared with 2 per cent for patients who
did not have steatohepatitis (odds ratio (OR) 10·5,
P = 0·001). In particular, patients with steatohepatitis had
a higher risk of death from postoperative liver failure
compared with all other patients (6 versus 1 per cent;
OR 7·7, P = 0·01) (Table 2). These ﬁndings suggest
that steatohepatitis may result in failure of the remnant
liver to regenerate following major hepatectomy, which
can lead to progressive liver failure. Given these data,
caution is advised when using irinotecan-based therapies
in patients with known steatosis or steatohepatitis, and in
patients at known risk for steatosis (for example with
a high BMI, diabetes mellitus, predisposing metabolic
syndrome).
Chemotherapy-associated hepatic sinusoidal
obstruction syndrome
SOS (veno-occlusive disease) was initially described in 1920
following a lethal intoxication by pyrrolizidine alkaloids
(present in some plants)58. For many years after that
initial report, SOS was observed only rarely. However,
with the introduction of bone marrow transplantation
and treatments involving combinations of several cytotoxic
drugs, the syndrome has become more prevalent22–24.
SOS following chemotherapy in a clinical context other
than bone marrow transplantation is rare59,60. The use of
oxaliplatin, however, has recently been implicated in the
development of hepatic SOS (Fig. 2).
The pathophysiology of SOS involves the depolymeriza-
tion of F-actin in sinusoidal endothelial cells, the activation
of metalloproteases61, and the consequent induction of
oxidative stress62. As noted previously, several chemother-
apeutic agents (5-FU, platinum derivatives and taxanes)
can induce oxidative stress56,57.
Oxaliplatin-associated sinusoidal obstruction
syndrome
Rubbia-Brandt et al.25 were the ﬁrst to report oxaliplatin-
associated SOS in the non-tumorous liver specimens of
patients undergoing hepatic resection following treatment
with oxaliplatin (Table 1). Perisinusoidal injuries, including
dilatation and congestion with ﬁbrosis and venous
occlusion, were present in 78 per cent of patients treated
with oxaliplatin. There was no correlation between the
cumulative dose of oxaliplatin and the presence or severity
of the sinusoidal injury (Table 1). Whether oxaliplatin is
solely responsible for sinusoidal injuries or whether such
injuries are linked to the combination of oxaliplatin with
other chemotherapeutic agents (such as 5-FU) has not
been fully investigated. Rubbia-Brandt and colleagues25
did not address the clinical impact of sinusoidal injuries on
outcome from hepatic resection.
Karoui et al.53 recently reported that systemic
chemotherapy was signiﬁcantly associated with
microvascular changes, such as sinusoidal dilatation
and hepatocyte necrosis, but it was not associated
with fatty degeneration. Liver injury was not stratiﬁed
by chemotherapy regimen type (although two-thirds
of patients received oxaliplatin), and all patients had
undergone total vascular exclusion, so meaningful
conclusions regarding regimen-speciﬁc liver injuries
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a  Whole liver with SOS
b  Cut liver with SOS c  Sinusoidal dilatation
Fig. 2 Spectrum of oxaliplatin-associated sinusoidal obstruction syndrome (SOS). a, b Macroscopic aspect of liver with
oxaliplatin-associated injury (‘blue’ liver). The distended sinusoids lead to entrapment of erythrocytes that in turn makes the liver blue
in colour (b courtesy of Dr 1. Brown, Brisbane, Queensland, Australia). c Microscopic demonstration of centrilobular sinusoidal
dilatation with only scattered macrovesicular steatosis (trichrome; magniﬁcation x100)
cannot be made. These authors did, however, demonstrate
that preoperative chemotherapy was associated with
increased postoperative morbidity (38 per cent in the
chemotherapy group versus 14 per cent in the control
group). The increased morbidity was mainly due to
a higher incidence of postoperative liver failure in
the chemotherapy group (11 per cent versus 0 per cent)
(Table 2). Furthermore, an increased risk of surgical
complications as the number of chemotherapy cycles
increased was reported (Table 1). Perioperative mortality,
however, was not associated with the number of
chemotherapy cycles.
The recent series from Vauthey et al.21 helped to clarify
that sinusoidal injury was more common with oxaliplatin
than with other chemotherapeutic regimens. Oxaliplatin
therapy was associated with sinusoidal dilatation nearly ﬁve
times more often than therapy with irinotecan (19 versus
4 per cent). The risk of SOS did not seem to increase with
increasing duration of chemotherapy, but most patients
in the study had received relatively short-course therapy
(3–4 months of preoperative chemotherapy). Importantly,
the same study21 conﬁrmed the ﬁndings of others63
that short-course oxaliplatin therapy was not associated
with increased morbidity or mortality following hepatic
resection. Speciﬁcally, no deaths occurred among the 22
patients with moderate to severe sinusoidal injury.
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Floxuridine-associated liver injury
In 1985, Kemeny and co-workers64 ﬁrst described hepatic
artery infusion chemotherapy as adjuvant treatment after
resection of CLM. This requires implantation of an intra-
arterial catheter via a port or pump, which allows the
infusion of high-dose cytotoxic agents directly into the
liver via the hepatic artery. Floxuridine has an extraction
rate of 94–99 per cent in the liver during the ﬁrst pass,
making it a particularly good candidate for use in this
context. Although hepatic artery infusion was designed to
optimize delivery of chemotherapy to the liver directly, few
studies have reported beneﬁts65–67. Despite the suggestion
of good locoregional response rates, a systematic review
of seven randomized trials of such therapy including 592
patients failed to ﬁnd a signiﬁcant improvement in long-
term survival with this approach68.
The hepatotoxicity of ﬂoxuridine is reported to be
dependent on both the dose and duration of treatment69.
Damage to the intrahepatic and extrahepatic bile ducts
has also been reported in up to 25 per cent of patients69.
The classical bile duct sclerosis associated with hepatic
artery infusion principally involves the extrahepatic biliary
tract and often spares the distal common bile duct. Bile
duct sclerosis is probably a result of ischaemia secondary
to small vessel arteritis70. Another recent study reported
biliary sclerosis in six of 17 patients (35 per cent) who
received such treatment; two of the affected patients died
from sepsis and liver failure71. Overall, reported rates of
biliary injury after hepatic artery infusion chemotherapy
range from 20 to 35 per cent65,71–74.
Hepatic parenchymal changes may include mild to
moderate triaditis, portal ﬁbrosis with bridging, ductular
proliferation, cholestasis and central vein ﬁbrosis75. In a
study of 168 patients, Link et al.72 showed that sclerosing
cholangitis or liver cirrhosis developed in 38–41 per cent
of those who had received ﬂoxuridine by hepatic artery
infusion; in contrast, no patient developed sclerosing
cholangitis or cirrhosis after treatment with 5-FU. Of
particular note, sclerosing cholangitis prevented potential
hepatic resection in the ﬂoxuridine group. These changes
can be responsible for an increased risk of bleeding during
surgery as the parenchyma tends to be more congested
and friable76,77. In one series, hepatic artery infusion
chemotherapy before hepatic resection was associated
with increased postoperative morbidity (57 per cent in the
treated group versus 18 per cent in the no-chemotherapy
group)76.
Support for use of hepatic artery infusion chemotherapy
before surgery is lacking. The reported rate of resectabil-
ity after such chemotherapy is less than 1 per cent78
compared with 10–13 per cent following oxaliplatin-based
chronomodulated systemic chemotherapy16. The evolu-
tion of systemic chemotherapy, with its increased response
rate and decreased risk of hepatotoxicity compared with
hepatic artery infusion, has reduced the theoretical advan-
tages of the latter. Furthermore, because stage IV colorectal
cancer is considered a systemic, not locoregional, disease,
the advantages of systemic chemotherapy that comple-
ments liver resection outweigh the potential beneﬁt of
intra-arterial therapy that is directed at the liver alone.
Implications for clinical practice
New chemotherapy treatments are associated with
improved overall survival in patients with stage IV col-
orectal cancer79. A proportion of patients with irre-
sectable CLM may undergo downsizing of liver disease
after systemic chemotherapy to enable potentially cura-
tive resection16. In addition, some patients with resectable
CLM may beneﬁt from chemotherapy. The rationale for
treating resectable tumours with systemic therapy includes
assessment of the efﬁcacy of the chosen regimen in
the individual patient (evaluation of tumour response),
observation of tumour biological behaviour in order to
spare non-responders non-therapeutic surgery, and poten-
tial downsizing of the tumour(s) to increase the chance
of complete resection and/or to spare normal hepatic
parenchyma.
The association between chemotherapy and steatosis
is not clear. Some studies suggest that patients who
receive chemotherapy develop steatosis45,49–51, whereas
others show no correlation between any chemotherapy
regimen and severe steatosis, when stratiﬁed for steatosis
and steatohepatitis21. Whether other variables, such as
weight gain during chemotherapy, steroids administered
to manage nausea during chemotherapy, or other factors,
modulate risk for steatosis remains to be clariﬁed. Analysis
of existing data shows that major resection in patients with
severe steatosis is more difﬁcult, with an increased risk
primarily of bleeding and infectious complications. There
is no deﬁnite increase in postoperative mortality in patients
with simple steatosis, perhaps because liver regeneration is
not sufﬁciently impaired to interfere with liver functional
recovery.
Steatohepatitis appears to be a much more dangerous
entity. Steatohepatitis can progress to ﬁbrosis, cirrho-
sis and liver failure34–36, and appears to impair the
functional reserve and regenerative capacity of the liver
signiﬁcantly. Data suggest that irinotecan chemotherapy
is associated with the development of steatohepatitis in
some patients21,52. The recent ﬁnding that resection in
patients with steatohepatitis is associated with signiﬁcant
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mortality may affect decision making regarding selection
of chemotherapy in resectable or potentially resectable
situations. To date, information concerning the potential
impact of bevacizumab and cetuximab on the develop-
ment of liver injury is limited, but hepatic resection after
treatment with these agents requires further study.
Finally, it is evident that liver injuries are not
mutually exclusive. Patients with steatosis can develop
steatohepatitis, SOS and other injuries. Assessment of
the underlying liver is critical in selection of the type of
surgical resection. An extensive resection (up to 80 per cent
of the functional parenchyma) can be tolerated with
virtually no risk of death when the underlying liver is
normal80. In contrast, even a minor hepatectomy can
be dangerous in patients with a severely compromised
liver. Where steatosis, steatohepatitis and SOS fall on
the continuum of liver disease is not clearly deﬁned.
There is no prospective study to validate a systematic
approach to patients with chemotherapy-induced hepatic
injury. Percutaneous biopsymay be helpful in somepatients
to assess the underlying liver before planning treatment.
Liver injuries, however, can be characterized by a patchy
distribution in the liver, and sampling error may not
permit accurate estimation of the overall severity of liver
disease. In patients with suspicion of hepatic injury or at
high risk for hepatic injury, laparoscopy combining direct
inspection and core biopsy of the liver may be a useful
method for evaluation of chemotherapy-induced hepatic
injury.
Portal vein embolization may provide an important
functional test of liver reserve in patients with marginal
remnants. Patients with liver remnants that are inadequate
based on systematic liver volumetry are candidates for such
embolization18,80–83. In addition to absolute liver volume,
hypertrophy of the future liver remnant (FLR) in response
to embolization predicts outcome from hepatectomy84.
Portal vein embolization may provide information about
functional hepatic reserve to help determinewhethermajor
resection will be safe. If adequate hypertrophy occurs,
hepatectomy may be safe. Continuing chemotherapy
while embolization is performed does not impair hepatic
hypertrophy in response to portal vein embolization85. The
minimum FLR that must remain after resection in patients
with various types of chemotherapy-related liver injury
remains unknown. However, after analysis of currently
available data on the safe limits of liver resection based
on liver remnant volume, a general consensus has been
reached86. Portal vein embolization is indicated when the
FLR volume is 20 per cent or less of the total liver volume
(TLV) in patients with normal liver, 30 per cent or less of
theTLV in patients who have had extensive chemotherapy,
Future liver remnant
Normal liver18,80
≤ 20% ≤ 30% ≤ 40%
Extensive
chemotherapy81,82 Cirrhosis
83
Duration of chemotherapy?
BMI, diabetes, metabolic syndrome?
Laparoscopy/biopsy?
Fig. 3 Indications for portal vein embolization. There is
consensus that, in patients treated with aggressive preoperative
chemotherapy, the remnant liver volume should be at least
30 per cent of the total liver volume to avoid a high risk of
complications following hepatic resection. BMI, body mass index
and 40 per cent or less of the TLV in patients with well
compensated cirrhosis (Fig. 3).
Advances in chemotherapy and hepatic surgery have
expanded the pool of candidates for potentially curative
hepatic resection for CLM. Recognition of chemotherapy-
related liver injuries further emphasizes the need for
patient-by-patient, multidisciplinary planning to optimize
care.This implies that patients should be evaluated by expe-
rienced hepatic surgeons and medical oncologists before
starting therapy to avoid extensive and unnecessary treat-
ment. Similar response rates between 5-FU plus oxaliplatin
(FOLFOX) and 5-FU plus irinotecan (FOLFIRI) balanced
against the unique liver injuries associated with each – SOS
for FOLFOX and steatohepatitis for FOLFIRI – must be
considered when designing ﬁrst-line versus second-line
treatments for patients likely to have hepatic resection
for CLM. The ﬁnding that steatohepatitis is associated
with the risk of progressive hepatic failure and death after
resection, whereas SOS is not, should further inﬂuence
treatment planning.
Consideration must be given to patients with CLM
who may proceed to surgery, particularly those with
the currently known risk factors for steatohepatitis,
including a BMI exceeding 25 kg/m2, diabetes mellitus
and pre-existing steatosis. Future challenges include the
reﬁnement of liver function assessment, the establishment
of better methods for evaluation and diagnosis of liver
injury, and the discovery of means to protect the
liver parenchyma from chemotherapy-induced injuries.
Response to treatment should no longer be the only
consideration when selecting treatment for patients
with CLM.
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